Silver Lake Enters Into Exclusive Negotiations to Acquire Groupe Meilleurtaux
22.7.2020 21:49:00 EEST | Business Wire | Press release
Groupe Meilleurtaux (“the Company”), a leading French financial services provider, Silver Lake, a global technology investment firm, and West Street Capital Partners VII (a fund managed by the Goldman Sachs Merchant Banking Division), today announced that they have entered into exclusive negotiations under which Silver Lake would acquire a majority stake in Groupe Meilleurtaux from West Street Capital Partners VII. Management would re-invest in Meilleurtaux alongside Silver Lake.
Hervé Hatt and Guillaume Autier, Chairman and CEO of Groupe Meilleurtaux, said: “We are extremely proud of what Meilleurtaux has achieved over the past three years, with the group’s revenue doubling between 2017 and 2019. Together with our outstanding team, our franchisees, and our partners, we have built a highly successful business with a strong track record of increasing transparency and access to the French financial services ecosystem. As Meilleurtaux begins its new chapter of growth, we are thrilled to welcome Silver Lake, a world-class technology investor with deep financial services and online industry expertise as well as strong value-creation capabilities, as our new majority investor. This investment marks a pivotal step for our company, and we are excited to lead it through this journey.”
Christian Lucas, Co-Head of Silver Lake EMEA, said: “Meilleurtaux is an exceptional company with a unique value proposition across its ecosystem of customers, channel partners and financial providers. We are highly impressed by the way Hervé, Guillaume and the rest of the team have strengthened the business and built it into a multi-channel financial services powerhouse with some 90 million online and mobile visits per year across its various properties. Investing in high-growth, impactful and pioneering business models is at the core of Silver Lake’s DNA, and the privilege of partnering with this management team as Meilleurtaux enters a new phase of growth and value creation is firmly consistent with our mission.”
Michele Titi-Cappelli, Managing Director and Alexandre Flavier, Executive Director of Goldman Sachs, added: “Meilleurtaux is an outstanding platform that plays a pivotal role in democratizing transparency and consumer choice in the French financial services ecosystem. We couldn’t be more pleased with the success of Meilleurtaux under the leadership of Hervé, Guillaume and their team since 2017. We strongly believe that Meilleurtaux is still at the beginning of its growth journey.”
Founded in 1999 and headquartered in Paris, France, Groupe Meilleurtaux provides a broad and diversified range of financial services and products that started historically with mortgage loan comparison and brokerage. Its wide suite of high-quality solutions is seamlessly accessible to consumers through a comprehensive range of leading online and mobile tools including its flagship websites Meilleurtaux.com, Lecomparateurassurance.com and Meilleurplacement.com, as well as financial information website MoneyVox, which in aggregate attract an industry-leading number of approximately 90 million yearly visits. Meilleurtaux.com’s award winning and web-native digital solutions comprise a set of innovative, client-centric toolkits including intuitive financial simulators, calculators and barometers focused solely on helping households save money across their most important financial life decisions on a daily basis. The Company’s unique multi-channel offering is enabled by France’s largest network of 340 brokerage branches, offering customers an unmatched service level in partnership with an industry leading network of more than 300 established bank and insurance providers that together have shaped Meilleurtaux’s trusted brand for over two decades.
Silver Lake is planning to invest heavily in Groupe Meilleurtaux’s product range and partnership network to help further accelerate the Company’s strong organic and inorganic revenue growth across its core business of mortgage and loan insurance brokerage, as well as to further expand its leading offering across the financial services ecosystem. Silver Lake will thereby preserve Groupe Meilleurtaux’s winning operating model while leveraging its capabilities to support management in strengthening it further.
The proposed transaction is expected to close in the fourth quarter and is subject to regulatory approvals and works council information and consultation procedures.
From 1 August 2020 the Meilleurtaux Group’s leadership team will include Guillaume Autier as CEO and Thomas Kienzi as CFO, with Hervé Hatt as chairman of the Board.
About Groupe Meilleurtaux and Meilleurtaux.com
Founded in 1999 and headquartered in Paris, France, Groupe Meilleurtaux is a leading French financial services provider with a broad and diversified range of financial services including loan insurance and mortgage brokerage, debt consolidation solutions, savings & investment products as well as P&C and health insurance distribution and brokerage offerings, available both online and through France’s largest network of 340 brokerage branches. For more information, please visit meilleurtaux.com
About Silver Lake
Silver Lake is a global technology investment firm, with over $40 billion in combined assets under management and committed capital and a team of approximately 100 investment and operating professionals located in Silicon Valley, New York, London and Hong Kong. Silver Lake’s portfolio of investments collectively generates more than $230 billion of revenue annually and employs 370,000 people globally. For more information about Silver Lake and its portfolio, please visit silverlake.com.
About Goldman Sachs Merchant Banking Division
Founded in 1869, The Goldman Sachs Group, Inc. is a leading global investment banking, securities and investment management firm. Goldman Sachs Merchant Banking Division (MBD) is the primary center for the firm’s long-term principal investing activity. MBD is one of the leading private capital investors in the world with investments across private equity, infrastructure, private debt, growth equity and real estate.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200722005830/en/
Contact information
Media contacts
FOR SILVER LAKE:
Jennifer Stroud
jennifer.stroud@edelman.com
M: +1-646-565-1792
Virginie Spelle
virginie.spelle@elanedelman.com
M: +33 (0)6 34 03 15 00
FOR GOLDMAN SACHS MERCHANT BANKING DIVISION:
Joseph Stein
+44 20 7774 2523
FOR MEILLEURTAUX.COM:
Anne-Charlotte Neau
anne-charlotte.neau@taddeo.fr
+33(0)6 23 73 56 03
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom